Juul Releases 9 E-cigarette Research Findings on Harm, Quitting, Minors, and More

On March 15, according to the official website of e-cigarette company Juul, JUUL announced the findings of nine scientific studies and research programs at the Society for Research on Nicotine and Tobacco (SRNT) 2020 Annual Meeting in New Orleans on March 14 local time. The company said its research covers a wide range of topics and contributes to the growing body of scientific evidence on end products.
 
Below is the full list of JUUL Labs studies shared digitally at SRNT 2020:

Pharmacokinetic and pharmacodynamic evaluation of adult smokers using e-cigarettes, combustible cigarettes, and nicotine gum

The association between flavored e-cigarette use among underage smokers and subsequent smoking behavior

The association between the initial subjective effects of e-cigarette use among never-smokers and former smokers and later e-cigarette use and smoking behavior

A longitudinal study of factors associated with continued smoking versus intermittent smoking behavior among adult smokers using e-cigarettes (NES)

Factors associated with regular e-cigarette use among adult smokers who quit combustible cigarettes

Cigarette smoking and relapse behavior among adult former smokers who used e-cigarettes to quit smoking: a 12-month longitudinal study

Preliminary findings from a pilot program for a novel system designed to improve retailer compliance in tobacco product purchases

Real-time analysis of particle size distribution in aerosol from e-cigarettes during the liquefaction phase using an electrical low-pressure impactor

The impact of smoking on flavored e-cigarette use and switching behavior

JUUL said it has been conducting and supporting non-clinical, clinical, and behavioral research to study the public health impact of JUUL products, and is committed to working with regulators, public health officials, and other stakeholders to preserve the historic opportunity to move adult smokers away from combustible cigarettes while combating underage use. The company said it will continue to share the results of its scientific and research programs transparently with the public health community in an effort to support the scientific foundation of the category and future regulatory submissions.